Published in J Pharmacol Exp Ther on March 10, 2005
Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend (2008) 1.59
Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats. Br J Pharmacol (2013) 1.47
In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther (2011) 1.37
Intracranial self-stimulation to evaluate abuse potential of drugs. Pharmacol Rev (2014) 1.37
Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. Pharmacol Biochem Behav (2008) 1.33
Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther (2009) 1.17
Prolonged attenuation of the reinforcing strength of cocaine by chronic d-amphetamine in rhesus monkeys. Neuropsychopharmacology (2010) 1.13
Effects of chronic d-amphetamine administration on the reinforcing strength of cocaine in rhesus monkeys. Psychopharmacology (Berl) (2010) 1.08
Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder. Pharmacol Rev (2015) 1.06
Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J (2007) 1.06
Role of phenmetrazine as an active metabolite of phendimetrazine: evidence from studies of drug discrimination and pharmacokinetics in rhesus monkeys. Drug Alcohol Depend (2012) 1.06
Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction. Exp Clin Psychopharmacol (2008) 1.06
Agonist Medications for the Treatment of Cocaine Use Disorder. Neuropsychopharmacology (2014) 1.04
Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine. J Pharmacol Exp Ther (2009) 1.03
Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend (2014) 1.01
Agonist replacement therapy for cocaine dependence: a translational review. Future Med Chem (2012) 0.97
Preclinical Assessment of Lisdexamfetamine as an Agonist Medication Candidate for Cocaine Addiction: Effects in Rhesus Monkeys Trained to Discriminate Cocaine or to Self-Administer Cocaine in a Cocaine Versus Food Choice Procedure. Int J Neuropsychopharmacol (2015) 0.96
Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav (2009) 0.90
The role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals. Adv Pharmacol (2014) 0.90
Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys. Exp Clin Psychopharmacol (2014) 0.89
Lower reinforcing strength of the phenyltropane cocaine analogs RTI-336 and RTI-177 compared to cocaine in nonhuman primates. Pharmacol Biochem Behav (2010) 0.87
Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research. Pharmacol Rev (2016) 0.87
Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters. ACS Chem Neurosci (2012) 0.86
Changes in feeding and locomotion induced by amphetamine analogs in rats. Drug Alcohol Depend (2008) 0.86
Evidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates. Neuropsychopharmacology (2013) 0.85
Monoamine transporter inhibitors and substrates as treatments for stimulant abuse. Adv Pharmacol (2014) 0.84
Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey. Pharmacol Biochem Behav (2009) 0.83
Rate-dependent effects of monoamine releasers on intracranial self-stimulation in rats: implications for abuse liability assessment. Behav Pharmacol (2013) 0.83
Nonhuman primate neuroimaging and cocaine medication development. Exp Clin Psychopharmacol (2008) 0.82
Serotonin (5-HT) precursor loading with 5-hydroxy-l-tryptophan (5-HTP) reduces locomotor activation produced by (+)-amphetamine in the rat. Drug Alcohol Depend (2010) 0.82
Effects of chronic methylphenidate on cocaine self-administration under a progressive-ratio schedule of reinforcement in rhesus monkeys. J Pharmacol Exp Ther (2013) 0.80
Perinatal lead exposure alters locomotion induced by amphetamine analogs in rats. Life Sci (2011) 0.77
Synthesis and biological characterization of (3R,4R)-4-(2-(benzhydryloxy)ethyl)-1-((R)-2-hydroxy-2-phenylethyl)-piperidin-3-ol and its stereoisomers for activity toward monoamine transporters. ChemMedChem (2009) 0.77
EVALUATION OF DRUG ABUSE TREATMENT MEDICATIONS: CONCORDANCE BETWEEN CLINICAL AND PRECLINICAL STUDIES. NIDA Res Monogr (2005) 0.76
Chronic treatment with monoamine oxidase-B inhibitors decreases cocaine reward in mice. Psychopharmacology (Berl) (2009) 0.76
Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs. Curr Top Behav Neurosci (2016) 0.75
Alpha-ethyltryptamines as dual dopamine-serotonin releasers. Bioorg Med Chem Lett (2014) 0.75
Repeated administration of the 5-HT1B/1A agonist, RU 24969, facilitates the acquisition of MDMA self-administration: role of 5-HT1A and 5-HT1B receptor mechanisms. Psychopharmacology (Berl) (2016) 0.75
Predicting new molecular targets for known drugs. Nature (2009) 9.71
Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci U S A (2007) 7.96
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
Relating protein pharmacology by ligand chemistry. Nat Biotechnol (2007) 6.61
Structure of the human κ-opioid receptor in complex with JDTic. Nature (2012) 5.18
Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. J Clin Invest (2011) 5.12
Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron (2009) 4.98
Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest (2006) 4.77
Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem (2003) 4.36
The expanded biology of serotonin. Annu Rev Med (2009) 3.87
Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology (2003) 3.78
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol (2011) 3.60
Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest (2006) 3.59
Generation of a synthetic memory trace. Science (2012) 3.55
Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization. Nat Neurosci (2010) 3.55
The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science (2004) 3.54
Automated design of ligands to polypharmacological profiles. Nature (2012) 3.54
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 3.35
Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron (2005) 3.30
Endocrine regulation of male fertility by the skeleton. Cell (2011) 3.20
Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature (2011) 3.19
Structure of the human smoothened receptor bound to an antitumour agent. Nature (2013) 3.08
Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature (2012) 2.96
Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther (2005) 2.66
Remote control of neuronal signaling. Pharmacol Rev (2011) 2.66
Monoamine transporters and psychostimulant drugs. Eur J Pharmacol (2003) 2.60
Structural features for functional selectivity at serotonin receptors. Science (2013) 2.60
Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav (2004) 2.52
Engineering GPCR signaling pathways with RASSLs. Nat Methods (2008) 2.29
Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol (2011) 2.10
Inhibition of mediodorsal thalamus disrupts thalamofrontal connectivity and cognition. Neuron (2013) 2.01
DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Annu Rev Pharmacol Toxicol (2014) 1.99
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A (2011) 1.98
Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther (2004) 1.97
Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov (2005) 1.93
Chemogenetic tools to interrogate brain functions. Annu Rev Neurosci (2014) 1.92
G-protein-coupled receptors at a glance. J Cell Sci (2003) 1.92
A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A (2009) 1.90
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol (2013) 1.89
Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol (2004) 1.88
Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther (2009) 1.88
Structural basis for molecular recognition at serotonin receptors. Science (2013) 1.86
N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology (2007) 1.83
Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists. J Neurosci (2002) 1.80
Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist. J Med Chem (2005) 1.78
Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology (2004) 1.71
In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther (2003) 1.70
A pharmacological organization of G protein-coupled receptors. Nat Methods (2013) 1.65
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA). Bioorg Med Chem Lett (2004) 1.65
Explaining the escalation of drug use in substance dependence: models and appropriate animal laboratory tests. Pharmacology (2007) 1.62
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors. J Med Chem (2003) 1.62
Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev Pharmacol Toxicol (2011) 1.61
Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology (Berl) (2003) 1.59
Mining the receptorome. J Biol Chem (2004) 1.58
New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol Pharmacol (2008) 1.57
Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol Depend (2003) 1.56
Molecular biology of serotonin receptors structure and function at the molecular level. Curr Top Med Chem (2002) 1.54
Management of pneumothorax. Semin Respir Crit Care Med (2011) 1.53
Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology (Berl) (2014) 1.48
3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol (2003) 1.47
In silico molecular comparisons of C. elegans and mammalian pharmacology identify distinct targets that regulate feeding. PLoS Biol (2013) 1.47
PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci (2009) 1.46
Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader-Willi syndrome. Neurobiol Dis (2010) 1.46
Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull (2007) 1.45
Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol (2009) 1.44
Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci (2003) 1.42
Chest ultrasonography: where's the beef? Chest (2011) 1.39
First, do no harm: less training ≠ quality care. Am J Crit Care (2012) 1.38
CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci (2010) 1.38
Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Neuropsychopharmacology (2007) 1.38
Chemical informatics and target identification in a zebrafish phenotypic screen. Nat Chem Biol (2011) 1.37
Engineered GPCRs as tools to modulate signal transduction. Physiology (Bethesda) (2008) 1.37
Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected Galphaq-coupled protein receptors. J Biol Chem (2004) 1.37
In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther (2011) 1.37
Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci U S A (2012) 1.36
Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology (2003) 1.35
Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther (2006) 1.35
Preclinical Determinants of Drug Choice under Concurrent Schedules of Drug Self-Administration. Adv Pharmacol Sci (2012) 1.34
Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice. Neurotoxicology (2012) 1.33
Effects of pain- and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior. Pain (2009) 1.32
Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion. Am J Med (2007) 1.29
A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. J Biol Chem (2003) 1.28
Effects of low- and high-nicotine cigarette smoking on mood states and the HPA axis in men. Neuropsychopharmacology (2005) 1.28
Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) (2009) 1.28
Massively parallel screening of the receptorome. Comb Chem High Throughput Screen (2008) 1.27
Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J Biol Chem (2002) 1.27
Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs. Nat Protoc (2010) 1.26
Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci U S A (2009) 1.26
Delay discounting of saccharin in rhesus monkeys. Behav Processes (2009) 1.25
Effects of clomipramine on self-control choice in Lewis and Fischer 344 rats. Pharmacol Biochem Behav (2005) 1.24
Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev (2004) 1.24
The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. J Med Chem (2009) 1.24
Effects of delay to reinforcement on the choice between cocaine and food in rhesus monkeys. Psychopharmacology (Berl) (2006) 1.23